United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - cloxacillin benzathine (unii: ac79l7pv2g) (cloxacillin - unii:o6x5qgc2vb) - cloxacillin 500 mg in 7.5 ml - indications: orbenin-dc is indicated in the treatment and prophylaxis of bovine mastitis in nonlactating cows due to staphylococcus aureus and streptococcus agalactiae . contraindications: because cloxacillin benzathine is relatively insoluble, orbenin-dc's activity will be prolonged. therefore, orbenin-dc should not be used for the occasional cow which may have a dry period of less than 4 weeks. this precaution will avoid residues in the milk following removal of the colostrum.

United States - English - NLM (National Library of Medicine)

boehringer ingelheim animal health usa inc. - cloxacillin benzathine (unii: ac79l7pv2g) (cloxacillin - unii:o6x5qgc2vb) - cloxacillin 500 mg in 10 ml - for the treatment of mastitis in dairy cows during the dry period. dry-clox has been shown by extensive clinical studies to be efficacious in the treatment of mastitis in dry cows, when caused by streptococcus agalactiae and staphylococcus aureus including penicillin-resistant strains. treatment of the dry cow with dry-clox is indicated in any cow known to harbor any of these organisms in the udder at drying off, or which has had repeated attacks of mastitis during the previous lactation, or is affected with mastitis at drying off, if caused by susceptible organisms.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - cloxacillin as the benzathine salt; brilliant blue dye - misc. intra mammary - cloxacillin as the benzathine salt antibiotic active 500.0 mg/sg; brilliant blue dye dye-blue other 25.0 mg/sg - antibiotic & related - cattle | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | heifer | steer - mastitis | organisms sensitive to cloxacillin | subclinical mastitis

Ireland - English - HPRA (Health Products Regulatory Authority)

zoetis belgium s.a. - cloxacillin (as cloxacillin benzathine bp (vet)) - intramammary suspension - 500 mg/syringe - cloxacillin - bovine - antibacterial

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - cloxacillin benzathine - unknown - cloxacillin benzathine antibiotic active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

norbrook laboratories australia pty limited - cloxacillin benzathine - unknown - cloxacillin benzathine antibiotic active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

norbrook laboratories australia pty limited - cloxacillin benzathine - unknown - cloxacillin benzathine antibiotic active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

avet health limited - cloxacillin benzathine - unknown - cloxacillin benzathine antibiotic active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - cloxacillin benzathine - unknown - cloxacillin benzathine antibiotic active 0.0 - active constituent

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 250 mg - the penicillinase-resistant penicillins are indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs. cultures and susceptibility tests should be performed initially to determine the causative organism and their sensitivity to the drug (see clinical pharmacology – susceptibility testing ). the penicillinase-resistant penicillins may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. the penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dic